17-43106477-C-T

Variant summary

Our verdict is Pathogenic.
>+14 Pathogenic
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received 22 classification points (ACMG Germline Pathogenicity v2019). PVS1PS3PM2PP5_Very_Strong

The NM_001407853.1(BRCA1):c.2+1G>A variant causes a splice donor, intron change involving the alteration of a non-conserved nucleotide. Note: NM_001407853.1 is not a MANE Select or MANE Plus Clinical transcript for BRCA1; the reported annotation may differ from that of the MANE-designated reference transcript for this gene. The variant is predicted to lead to nonsense-mediated mRNA decay (NMD). The variant allele was found at a cumulative frequency of 0.00000138 (AC=2) in the gnomAD database across 1,449,660 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.000000907. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★★). ClinVar reports functional evidence for this variant: "SCV000075654: Experimental studies have shown that this missense change affects BRCA1 function (PMID:7894491, 8944023, 11326114, 19287957, 24516540)." and additional evidence is available in ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.C64G: Pathogenic (ClinVar VariationId 17660, 2 stars) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.C64= (synonymous): unknown significance (ClinVar VariationId 867931); p.C64F: unknown significance (ClinVar VariationId 867930) This exact variant is curated in the UniProt human variants database as Uncertain Significance.

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )

Consequence

BRCA1
NM_001407853.1 splice_donor, intron

Scores

13
5
1

Clinical Significance

Pathogenic reviewed by expert panel P:29

Conservation

PhyloP100: 4.11

Publications

59 publications found
Variant links:
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
BRCA1 Gene-Disease associations (from GenCC):
  • BRCA1-related cancer predisposition
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • breast-ovarian cancer, familial, susceptibility to, 1
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • Fanconi anemia, complementation group S
    Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae), ClinGen
  • pancreatic cancer, susceptibility to, 4
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • hereditary breast ovarian cancer syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_001407853.1, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACMG Germline Pathogenicity v2019

Classification was made for transcript:

Our verdict: Pathogenic. The variant received 22 points.

PVS1Null variant in LOF gene
Splice site frameshift, NMD predicted, LoF disease mechanism — very strong (PVS1); Splice donor variant predicted to cause a frameshift, triggering NMD. Loss of function is a known disease mechanism for this gene.
PS3Functional studies show damaging effect
Well-established functional study supports damaging effect (PS3); SCV000075654: Experimental studies have shown that this missense change affects BRCA1 function (PMID: 7894491, 8944023, 11326114, 19287957, 24516540).; SCV000918679: Several publications report experimental evidence evaluating an impact on protein function (example, Findlay_2018). The most pronounced variant effect results in a loss of homology directed repair (HDR) activity.; SCV005374666: "Reported by one calibrated study to exhibit protein function similar to pathogenic control variants." PMID: 30209399; SCV003927164: Experimental studies have shown that this missense change abolishes E3 ubiquitin ligase activity (PMID: 11320250).; SCV000186951: "This alteration is located in the highly conserved 5' RING domain and has been shown to result in abolished ubiquitin protein ligase activity (Ruffner H et al.Proc Natl Acad Sci USA. 2001 Apr 24;98(9):5134-9)."; SCV000911053: Functional studies have reported that this variant impacts BRCA1 function in ubiquitin ligase, BARD1 binding, haploid cell proliferation and yeast colony size assays (PMID: 11320250, 12732733, 25823446, 27272900, 30209399).; SCV000292502: Published functional studies demonstrate a damaging effect: reduced or absent ubiquitin ligase activity, decreased BARD1 binding, decreased cell survival, and abnormal yeast colony size and spot formation (Ruffner 2001, Starita 2015, Thouvenot 2016, Findlay 2018); SCV000600273: Multiple functional studies have demonstrated that this variant has a damaging effect on BRCA1 protein function (PMID: 30209399 (2018), 27272900 (2016), 25823446 (2015), 23397983 (2014), 22034289 (2012), 15131401 (2004), 8944023 (1996)).; SCV004101417: Reported by one calibrated study to exhibit protein function similar to pathogenic control variants (PMID: 30209399) (PS3 met).
PM2Absent/extremely low in population databases
Very rare in gnomAD for AD/XL gene (popmax AF < threshold/10) — PM2; GnomAD popmax AF = 0.000000907 — very rare for AD+AR gene (threshold 0.0001) — PM2 moderate.
PP5Reputable source reports pathogenic
ClinVar ≥3 stars pathogenic — very strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 3 star(s). ClinVar submissions strongly and reliably favor pathogenicity (29/29 total P/LP).

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_001407853.1. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

BRCA1 NM_007294.4
MANE Select
HGVSc / HGVSpc.191G>Ap.Cys64Tyr
Exon rankExon 4 of 23
missense
Prot: NP_009225.1UniProt: P38398-1
BRCA1 NM_001407853.1
HGVSc / HGVSpc.2+1G>A
Exon rankIntron 4 of 23
splice_donorintron
Prot: NP_001394782.1
BRCA1 NM_001407879.1
HGVSc / HGVSpc.2+1G>A
Exon rankIntron 4 of 22
splice_donorintron
Prot: NP_001394808.1

Ensembl Transcripts

BRCA1 ENST00000357654.9
TSL:1MANE Select
HGVSc / HGVSpc.191G>Ap.Cys64Tyr
Exon rankExon 4 of 23
missense
Prot: ENSP00000350283.3UniProt: P38398-1
BRCA1 ENST00000471181.7
TSL:1
HGVSc / HGVSpc.191G>Ap.Cys64Tyr
Exon rankExon 4 of 24
missense
Prot: ENSP00000418960.2UniProt: P38398-7
BRCA1 ENST00000470026.6
TSL:1
HGVSc / HGVSpc.191G>Ap.Cys64Tyr
Exon rankExon 4 of 23
missense
Prot: ENSP00000419274.2UniProt: P38398-1

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 5 sources
GnomAD3 genomes
Cov:32
GnomAD4 exome
AF: 0.00000138
AC:2
Hom:0
AN:1449660
Cov:28
GnomAD4 genome
Cov:32
TOPMed (Bravo)
AF: 0.00000378
ALFA (dbGaP/dbSNP Allele Frequency Aggregator)
AF: 0.00000482
AC:1
Hom:0
AN:207320
Showing 5 sources

Case/control cohorts

CohortCasesControls
AFACANAFACAN
Epi25
(Epilepsy)
0.0000240 141692 0.00 066720
SCHEMA
(Schizophrenia)
0.0000148 167778 0.00 0132972
Showing 2 cohortsAllele count / allele number. AF is computed from the counts for ASC (not provided by the source).

ClinVar

ClinVar submissions
Significance:Pathogenic
Revision:reviewed by expert panel
View on ClinVar
Pathogenic
VUS
Benign
Condition
11
-
-
Breast-ovarian cancer, familial, susceptibility to, 1 (11)
8
-
-
not provided (8)
5
-
-
Hereditary breast ovarian cancer syndrome (5)
2
-
-
Hereditary cancer-predisposing syndrome (2)
1
-
-
BRCA1-related cancer predisposition (1)
1
-
-
Inherited prostate cancer (1)
1
-
-
Pancreatic cancer, susceptibility to, 4 (1)

Computational Scores

AlphaGenome AVI
Pathogenic35
AlphaMissense
Pathogenic0.99
BayesDel_addAF
Pathogenic0.55D
BayesDel_noAF
Pathogenic0.56
CADD
Pathogenic29
DANN
Uncertain0.99
DEOGEN2
Uncertain0.48T
Eigen
Pathogenic0.88
Eigen_PC
Pathogenic0.76
FATHMM_MKL
Uncertain0.96D
FuncVEP CTI
Pathogenic0.99
GPN-Star LLR
N/A-8.1
GPN-Star score
N/A8.1
LIST_S2
Uncertain0.97D
M_CAP
Pathogenic0.95D
MetaRNN
Pathogenic0.99D
MetaSVM
Pathogenic0.95D
Mutation Taster
N/A0/100disease causing (ClinVar)
MutationAssessor
Pathogenic4.3H
PhyloP100
Uncertain4.1
popEVE
Benign-4.4
PrimateAI
Pathogenic0.80T
PROVEAN
Benign-2.2N
RBP_binding_hub_radar
N/A0.0
RBP_regulation_power_radar
N/A1.7
REVEL
Pathogenic0.95
Sift
Pathogenic0.0D
Sift4G
Uncertain0.0090D
Varity_R
N/A0.98
VESM-3B
Benign-12
Showing 30 of 30 scores

Splicing Scores

Pangolin (max)
Benign0.030
SpliceAI score (max)
Benign0.0
Details are displayed if max score is > 0.2
Splicevardb
N/A2.0
Showing 3 of 3 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

1 abnormal
3 no calibration
Nucleotide level
BRCA1 SGE Normalized Scores
Meta-analysis of urn:mavedb:00000097-a-1, urn:mavedb:00000097-b-1, urn:mavedb:00000097-c-1, urn:mavedb:00000097-d-1, urn:mavedb:00000097-e-1 and 21 others
Gene
BRCA1
Assay type
Cell fitness
Mechanism
Molecular function
Model system
Immortalized human cells (Homo sapiens)
Score
-2.05
Classified as
PS3 strongFunctionally abnormalFayer calibration: Non-functional
+4 more calibrations
PS3 strongFunctionally abnormalIGVF Coding Variant Focus Group -- Controls: Missense Variants Only: Non-functional
PS3 strongFunctionally abnormalIGVF Coding Variant Focus Group -- Controls: All Variants: Non-functional
PS3 strongFunctionally abnormalRUO
ExCALIBR calibration: PS3 Strong (7)
PS3 strongFunctionally abnormalRUO
ExCALIBR calibration (ClinVar 2018): PS3 Strong (5)
Nucleotide level
Enrich2 nucleotide variant scores for BRCA1 Y2H
BRCA1 Y2H
Gene
BRCA1
Score
-2.04 · p.Cys63Tyr (assay numbering)
No calibration data
This score is at approximately the 4th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Nucleotide level
Enrich2 nucleotide variant scores for BRCA1 E3
BRCA1 E3
Gene
BRCA1
Score
· p.Cys63Tyr (assay numbering)
No calibration data
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Nucleotide level
BASE_ACMG quantities derived from the RING domain M2H functional assay
Functional Evaluation of BRCA1 RING Domain Missense Substitutions
Gene
BRCA1 translation start through RING domain
Score
9.69 · p.Cys64Tyr (assay numbering)
No calibration data
This score is at approximately the 89th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.